Conversely, when conditions permit, maximizing the reduction of postoperative GH levels could be a favorable option for clinicians, as it helps to correct endocrine dysfunction to the greatest extent and may reduce the risk of tumor recurrence [5]. The gene discussed is GH1; the disease is neoplasm.